Literature DB >> 30561796

Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.

Renée T Fortner1, Elizabeth M Poole2, Nicolas A Wentzensen3, Britton Trabert3, Emily White4, Alan A Arslan5, Alpa V Patel6, V Wendy Setiawan7, Kala Visvanathan8, Elisabete Weiderpass9,10,11,12, Hans-Olov Adami13, Amanda Black3, Leslie Bernstein14, Louise A Brinton3, Julie Buring13,15, Tess V Clendenen5, Agnès Fournier16,17, Gary Fraser18, Susan M Gapstur6, Mia M Gaudet6, Graham G Giles19,20, Inger T Gram9, Patricia Hartge3, Judith Hoffman-Bolton8, Annika Idahl21, Rudolf Kaaks1, Victoria A Kirsh22, Synnove Knutsen18, Woon-Puay Koh23, James V Lacey14, I-Min Lee13,15, Eva Lundin24, Melissa A Merritt25,26, Roger L Milne19,20, N Charlotte Onland-Moret27, Ulrike Peters4, Jenny N Poynter28, Sabina Rinaldi29, Kim Robien30, Thomas Rohan31, Maria-José Sánchez32,33, Catherine Schairer3, Leo J Schouten34, Anne Tjonneland35, Mary K Townsend36, Ruth C Travis37, Antonia Trichopoulou38,39, Piet A van den Brandt34, Paolo Vineis26,40, Lynne Wilkens25, Alicja Wolk41, Hannah P Yang3, Anne Zeleniuch-Jacquotte5, Shelley S Tworoger2,13,36.   

Abstract

Ovarian cancer risk factors differ by histotype; however, within subtype, there is substantial variability in outcomes. We hypothesized that risk factor profiles may influence tumor aggressiveness, defined by time between diagnosis and death, independent of histology. Among 1.3 million women from 21 prospective cohorts, 4,584 invasive epithelial ovarian cancers were identified and classified as highly aggressive (death in <1 year, n = 864), very aggressive (death in 1 to < 3 years, n = 1,390), moderately aggressive (death in 3 to < 5 years, n = 639), and less aggressive (lived 5+ years, n = 1,691). Using competing risks Cox proportional hazards regression, we assessed heterogeneity of associations by tumor aggressiveness for all cases and among serous and endometrioid/clear cell tumors. Associations between parity (phet = 0.01), family history of ovarian cancer (phet = 0.02), body mass index (BMI; phet ≤ 0.04) and smoking (phet < 0.01) and ovarian cancer risk differed by aggressiveness. A first/single pregnancy, relative to nulliparity, was inversely associated with highly aggressive disease (HR: 0.72; 95% CI [0.58-0.88]), no association was observed for subsequent pregnancies (per pregnancy, 0.97 [0.92-1.02]). In contrast, first and subsequent pregnancies were similarly associated with less aggressive disease (0.87 for both). Family history of ovarian cancer was only associated with risk of less aggressive disease (1.94 [1.47-2.55]). High BMI (≥35 vs. 20 to < 25 kg/m2 , 1.93 [1.46-2.56] and current smoking (vs. never, 1.30 [1.07-1.57]) were associated with increased risk of highly aggressive disease. Results were similar within histotypes. Ovarian cancer risk factors may be directly associated with subtypes defined by tumor aggressiveness, rather than through differential effects on histology. Studies to assess biological pathways are warranted.
© 2018 UICC.

Entities:  

Keywords:  aggressiveness; ovarian cancer; prospective cohort; risk factors; subtypes

Mesh:

Year:  2019        PMID: 30561796      PMCID: PMC6488363          DOI: 10.1002/ijc.32075

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  46 in total

Review 1.  The metabolic syndrome: A high-risk state for cancer?

Authors:  Stephanie Cowey; Robert W Hardy
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

2.  The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women.

Authors:  Kim N Danforth; A Heather Eliassen; Shelley S Tworoger; Stacey A Missmer; Robert L Barbieri; Bernard A Rosner; Graham A Colditz; Susan E Hankinson
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

3.  Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.

Authors:  Camilla Praestegaard; Allan Jensen; Signe M Jensen; Thor S S Nielsen; Penelope M Webb; Christina M Nagle; Anna DeFazio; Estrid Høgdall; Mary Anne Rossing; Jennifer A Doherty; Kristine G Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten Moysich; Roberta B Ness; Robert Edwards; Keitaro Matsuo; Satoyo Hosono; Ellen L Goode; Stacey J Winham; Brooke L Fridley; Daniel W Cramer; Kathryn L Terry; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Lisa E Paddock; Leon F Massuger; Nicolas Wentzensen; Paul Pharoah; Honglin Song; Alice Whittemore; Valerie McGuire; Weiva Sieh; Joseph Rothstein; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Alexandra Gentry-Maharaj; Anna H Wu; Celeste L Pearce; Malcolm Pike; Alice W Lee; Rebecca Sutphen; Jenny Chang-Claude; Harvey A Risch; Susanne K Kjaer
Journal:  Int J Cancer       Date:  2017-01-24       Impact factor: 7.396

4.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.

Authors:  Kristin M Nieman; Hilary A Kenny; Carla V Penicka; Andras Ladanyi; Rebecca Buell-Gutbrod; Marion R Zillhardt; Iris L Romero; Mark S Carey; Gordon B Mills; Gökhan S Hotamisligil; S Diane Yamada; Marcus E Peter; Katja Gwin; Ernst Lengyel
Journal:  Nat Med       Date:  2011-10-30       Impact factor: 53.440

5.  Improved classification of epithelial ovarian cancer: results of 3 danish cohorts.

Authors:  Karina Dahl Steffensen; Marianne Waldstrøm; Anni Grove; Bente Lund; Niels Pallisgård; Anders Jakobsen
Journal:  Int J Gynecol Cancer       Date:  2011-12       Impact factor: 3.437

6.  Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.

Authors:  Fanny Dao; Brooke A Schlappe; Jill Tseng; Jenny Lester; Alpa M Nick; Susan K Lutgendorf; Scott McMeekin; Robert L Coleman; Kathleen N Moore; Beth Y Karlan; Anil K Sood; Douglas A Levine
Journal:  Gynecol Oncol       Date:  2016-03-11       Impact factor: 5.482

7.  Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium.

Authors:  Jennifer Ose; Elizabeth M Poole; Helena Schock; Matti Lehtinen; Alan A Arslan; Anne Zeleniuch-Jacquotte; Kala Visvanathan; Kathy Helzlsouer; Julie E Buring; I-Min Lee; Anne Tjønneland; Laure Dossus; Antonia Trichopoulou; Giovanna Masala; N Charlotte Onland-Moret; Elisabete Weiderpass; Eric J Duell; Annika Idahl; Ruth C Travis; Sabina Rinaldi; Melissa A Merritt; Britton Trabert; Nicolas Wentzensen; Shelley S Tworoger; Rudolf Kaaks; Renée T Fortner
Journal:  Cancer Res       Date:  2017-04-05       Impact factor: 12.701

8.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.

Authors:  V Beral; R Doll; C Hermon; R Peto; G Reeves
Journal:  Lancet       Date:  2008-01-26       Impact factor: 79.321

9.  Ten-year relative survival for epithelial ovarian cancer.

Authors:  Lauren A Baldwin; Bin Huang; Rachel W Miller; Thomas Tucker; Scott T Goodrich; Iwona Podzielinski; Christopher P DeSimone; Fred R Ueland; John R van Nagell; Leigh G Seamon
Journal:  Obstet Gynecol       Date:  2012-09       Impact factor: 7.661

10.  Leptin stimulation of cell cycle and inhibition of apoptosis gene and protein expression in OVCAR-3 ovarian cancer cells.

Authors:  Anna Ptak; Elzbieta Kolaczkowska; Ewa L Gregoraszczuk
Journal:  Endocrine       Date:  2012-09-12       Impact factor: 3.633

View more
  11 in total

Review 1.  The role of immune dysfunction in obesity-associated cancer risk, progression, and metastasis.

Authors:  Aneesha Kulkarni; Laura W Bowers
Journal:  Cell Mol Life Sci       Date:  2021-01-19       Impact factor: 9.261

2.  A Multi-State Survival Model for Time to Breast Cancer Mortality among a Cohort of Initially Disease-Free Women.

Authors:  Bernard Rosner; Robert J Glynn; A Heather Eliassen; Susan E Hankinson; Rulla M Tamimi; Wendy Y Chen; Michelle D Holmes; Yi Mu; Cheng Peng; Graham A Colditz; Walter C Willett; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-08-02       Impact factor: 4.090

3.  Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3).

Authors:  Mary K Townsend; Britton Trabert; Renée T Fortner; Alan A Arslan; Julie E Buring; Brian D Carter; Graham G Giles; Sarah R Irvin; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Woon-Puay Koh; James V Lacey; Hilde Langseth; Susanna C Larsson; I-Min Lee; María Elena Martínez; Melissa A Merritt; Roger L Milne; Katie M O'Brien; Michael J Orlich; Julie R Palmer; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Kim Robien; Thomas E Rohan; Lynn Rosenberg; Sven Sandin; Dale P Sandler; Leo J Schouten; V Wendy Setiawan; Anthony J Swerdlow; Giske Ursin; Piet A van den Brandt; Kala Visvanathan; Elisabete Weiderpass; Alicja Wolk; Jian-Min Yuan; Anne Zeleniuch-Jacquotte; Shelley S Tworoger; Nicolas Wentzensen
Journal:  Int J Epidemiol       Date:  2022-06-13       Impact factor: 9.685

4.  Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3).

Authors:  Tianyi Huang; Mary K Townsend; Nicolas Wentzensen; Britton Trabert; Emily White; Alan A Arslan; Elisabete Weiderpass; Julie E Buring; Tess V Clendenen; Graham G Giles; I-Min Lee; Roger L Milne; N Charlotte Onland-Moret; Ulrike Peters; Dale P Sandler; Leo J Schouten; Piet A van den Brandt; Alicja Wolk; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-12       Impact factor: 4.254

5.  The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).

Authors:  Britton Trabert; Shelley S Tworoger; Katie M O'Brien; Mary K Townsend; Renée T Fortner; Edwin S Iversen; Patricia Hartge; Emily White; Pilar Amiano; Alan A Arslan; Leslie Bernstein; Louise A Brinton; Julie E Buring; Laure Dossus; Gary E Fraser; Mia M Gaudet; Graham G Giles; Inger T Gram; Holly R Harris; Judith Hoffman Bolton; Annika Idahl; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Marina Kvaskoff; James V Lacey; I-Min Lee; Roger L Milne; N Charlotte Onland-Moret; Kim Overvad; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Elio Riboli; Kim Robien; Thomas E Rohan; Dale P Sandler; Catherine Schairer; Leo J Schouten; Veronica W Setiawan; Anthony J Swerdlow; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Kala Visvanathan; Lynne R Wilkens; Alicja Wolk; Anne Zeleniuch-Jacquotte; Nicolas Wentzensen
Journal:  Cancer Res       Date:  2020-01-13       Impact factor: 12.701

6.  Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors.

Authors:  Yael Laitman; Rachel Michaelson-Cohen; Rakefet Chen-Shtoyerman; Yael Goldberg; Orit Reish; Rinat Bernstein-Molho; Ephrat Levy-Lahad; Noa Ephrat Ben Baruch; Inbal Kedar; D Gareth Evans; Sara Haim; Shani Paluch-Shimon; Eitan Friedman
Journal:  Fam Cancer       Date:  2020-11-09       Impact factor: 2.375

7.  Prediagnosis and postdiagnosis leisure time physical activity and survival following diagnosis with ovarian cancer.

Authors:  Tianyi Wang; Mary K Townsend; A Heather Eliassen; Kathryn L Terry; Mingyang Song; Melinda L Irwin; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2021-05-21       Impact factor: 7.316

8.  LINC01094/miR-577 axis regulates the progression of ovarian cancer.

Authors:  Jing Xu; Ping Zhang; Huajun Sun; Yang Liu
Journal:  J Ovarian Res       Date:  2020-10-17       Impact factor: 4.234

Review 9.  Metabolic risk factors of ovarian cancer: a review.

Authors:  Neda Khanlarkhani; Elham Azizi; Fardin Amidi; Mahshad Khodarahmian; Ensieh Salehi; Azar Pazhohan; Bagher Farhood; Keywan Mortezae; Nasser Hashemi Goradel; Maryam Shabani Nashtaei
Journal:  JBRA Assist Reprod       Date:  2022-04-17

10.  Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers.

Authors:  David W Chan; Wai-Yip Lam; Fushun Chen; Mingo M H Yung; Yau-Sang Chan; Wai-Sun Chan; Fangfang He; Stephanie S Liu; Karen K L Chan; Benjamin Li; Hextan Y S Ngan
Journal:  Clin Epigenetics       Date:  2021-07-22       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.